nodes	percent_of_prediction	percent_of_DWPC	metapath
Cefuroxime—Gastrointestinal symptom NOS—Sorafenib—liver cancer	0.0259	0.0267	CcSEcCtD
Cefuroxime—Haemoglobin decreased—Sorafenib—liver cancer	0.0221	0.0228	CcSEcCtD
Cefuroxime—Tubulointerstitial nephritis—Sorafenib—liver cancer	0.0199	0.0205	CcSEcCtD
Cefuroxime—Ceftriaxone—GLUL—liver cancer	0.0185	0.625	CrCbGaD
Cefuroxime—Blood bilirubin increased—Sorafenib—liver cancer	0.0161	0.0166	CcSEcCtD
Cefuroxime—Mouth ulceration—Sorafenib—liver cancer	0.0138	0.0142	CcSEcCtD
Cefuroxime—Prothrombin level increased—Epirubicin—liver cancer	0.0137	0.0141	CcSEcCtD
Cefuroxime—Prothrombin level increased—Doxorubicin—liver cancer	0.0127	0.0131	CcSEcCtD
Cefuroxime—Hepatic function abnormal—Sorafenib—liver cancer	0.0126	0.013	CcSEcCtD
Cefuroxime—Vaginal moniliasis—Epirubicin—liver cancer	0.0111	0.0115	CcSEcCtD
Cefuroxime—Vulvovaginal candidiasis—Epirubicin—liver cancer	0.0107	0.011	CcSEcCtD
Cefuroxime—Vaginal moniliasis—Doxorubicin—liver cancer	0.0103	0.0106	CcSEcCtD
Cefuroxime—Vulvovaginal mycotic infection—Epirubicin—liver cancer	0.0103	0.0106	CcSEcCtD
Cefuroxime—Local reaction—Epirubicin—liver cancer	0.0102	0.0105	CcSEcCtD
Cefuroxime—Toxic epidermal necrolysis—Sorafenib—liver cancer	0.00995	0.0103	CcSEcCtD
Cefuroxime—Vulvovaginal candidiasis—Doxorubicin—liver cancer	0.0099	0.0102	CcSEcCtD
Cefuroxime—Vulvovaginal mycotic infection—Doxorubicin—liver cancer	0.00952	0.00981	CcSEcCtD
Cefuroxime—Local reaction—Doxorubicin—liver cancer	0.0094	0.00969	CcSEcCtD
Cefuroxime—Vaginal discharge—Epirubicin—liver cancer	0.00925	0.00953	CcSEcCtD
Cefuroxime—Neutropenia—Sorafenib—liver cancer	0.00893	0.0092	CcSEcCtD
Cefuroxime—Vaginal discharge—Doxorubicin—liver cancer	0.00855	0.00882	CcSEcCtD
Cefuroxime—Infestation NOS—Sorafenib—liver cancer	0.00851	0.00877	CcSEcCtD
Cefuroxime—Infestation—Sorafenib—liver cancer	0.00851	0.00877	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Sorafenib—liver cancer	0.00844	0.0087	CcSEcCtD
Cefuroxime—Renal failure—Sorafenib—liver cancer	0.00837	0.00862	CcSEcCtD
Cefuroxime—Stomatitis—Sorafenib—liver cancer	0.0083	0.00855	CcSEcCtD
Cefuroxime—Jaundice—Sorafenib—liver cancer	0.0083	0.00855	CcSEcCtD
Cefuroxime—Hepatobiliary disease—Sorafenib—liver cancer	0.00805	0.0083	CcSEcCtD
Cefuroxime—Haemoglobin—Sorafenib—liver cancer	0.00768	0.00792	CcSEcCtD
Cefuroxime—Haemorrhage—Sorafenib—liver cancer	0.00764	0.00788	CcSEcCtD
Cefuroxime—Urinary tract disorder—Sorafenib—liver cancer	0.00755	0.00778	CcSEcCtD
Cefuroxime—Urethral disorder—Sorafenib—liver cancer	0.00749	0.00772	CcSEcCtD
Cefuroxime—Erythema multiforme—Sorafenib—liver cancer	0.00723	0.00745	CcSEcCtD
Cefuroxime—Angiopathy—Sorafenib—liver cancer	0.00693	0.00715	CcSEcCtD
Cefuroxime—Immune system disorder—Sorafenib—liver cancer	0.0069	0.00711	CcSEcCtD
Cefuroxime—Injection site pain—Epirubicin—liver cancer	0.00689	0.0071	CcSEcCtD
Cefuroxime—Erythema—Sorafenib—liver cancer	0.00665	0.00686	CcSEcCtD
Cefuroxime—Muscle spasms—Sorafenib—liver cancer	0.0064	0.00659	CcSEcCtD
Cefuroxime—Injection site pain—Doxorubicin—liver cancer	0.00637	0.00657	CcSEcCtD
Cefuroxime—Angioedema—Sorafenib—liver cancer	0.00608	0.00627	CcSEcCtD
Cefuroxime—Leukopenia—Sorafenib—liver cancer	0.00596	0.00614	CcSEcCtD
Cefuroxime—Blood bilirubin increased—Epirubicin—liver cancer	0.00595	0.00613	CcSEcCtD
Cefuroxime—Creatinine increased—Epirubicin—liver cancer	0.00591	0.00609	CcSEcCtD
Cefuroxime—Cough—Sorafenib—liver cancer	0.00581	0.00598	CcSEcCtD
Cefuroxime—Arthralgia—Sorafenib—liver cancer	0.00566	0.00584	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00563	0.0058	CcSEcCtD
Cefuroxime—Phosphatase alkaline increased—Epirubicin—liver cancer	0.00562	0.0058	CcSEcCtD
Cefuroxime—Vaginal inflammation—Epirubicin—liver cancer	0.00562	0.0058	CcSEcCtD
Cefuroxime—Blood bilirubin increased—Doxorubicin—liver cancer	0.0055	0.00567	CcSEcCtD
Cefuroxime—Creatinine increased—Doxorubicin—liver cancer	0.00547	0.00563	CcSEcCtD
Cefuroxime—Salivary hypersecretion—Epirubicin—liver cancer	0.00546	0.00563	CcSEcCtD
Cefuroxime—Anaphylactic shock—Sorafenib—liver cancer	0.00543	0.0056	CcSEcCtD
Cefuroxime—Colitis—Epirubicin—liver cancer	0.0054	0.00557	CcSEcCtD
Cefuroxime—Candida infection—Epirubicin—liver cancer	0.00537	0.00553	CcSEcCtD
Cefuroxime—Thrombocytopenia—Sorafenib—liver cancer	0.00532	0.00548	CcSEcCtD
Cefuroxime—Blood urea increased—Epirubicin—liver cancer	0.00531	0.00547	CcSEcCtD
Cefuroxime—Vaginal infection—Epirubicin—liver cancer	0.00531	0.00547	CcSEcCtD
Cefuroxime—Aplastic anaemia—Epirubicin—liver cancer	0.00528	0.00544	CcSEcCtD
Cefuroxime—Skin disorder—Sorafenib—liver cancer	0.00527	0.00544	CcSEcCtD
Cefuroxime—Phosphatase alkaline increased—Doxorubicin—liver cancer	0.0052	0.00536	CcSEcCtD
Cefuroxime—Vaginal inflammation—Doxorubicin—liver cancer	0.0052	0.00536	CcSEcCtD
Cefuroxime—Anorexia—Sorafenib—liver cancer	0.00518	0.00533	CcSEcCtD
Cefuroxime—Mouth ulceration—Epirubicin—liver cancer	0.00509	0.00524	CcSEcCtD
Cefuroxime—Salivary hypersecretion—Doxorubicin—liver cancer	0.00505	0.00521	CcSEcCtD
Cefuroxime—Colitis—Doxorubicin—liver cancer	0.005	0.00515	CcSEcCtD
Cefuroxime—Candida infection—Doxorubicin—liver cancer	0.00497	0.00512	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00495	0.0051	CcSEcCtD
Cefuroxime—Vaginal infection—Doxorubicin—liver cancer	0.00491	0.00506	CcSEcCtD
Cefuroxime—Blood urea increased—Doxorubicin—liver cancer	0.00491	0.00506	CcSEcCtD
Cefuroxime—Aplastic anaemia—Doxorubicin—liver cancer	0.00489	0.00504	CcSEcCtD
Cefuroxime—Dyspnoea—Sorafenib—liver cancer	0.00484	0.00499	CcSEcCtD
Cefuroxime—Dyspepsia—Sorafenib—liver cancer	0.00478	0.00493	CcSEcCtD
Cefuroxime—Decreased appetite—Sorafenib—liver cancer	0.00472	0.00486	CcSEcCtD
Cefuroxime—Thrombophlebitis—Epirubicin—liver cancer	0.00472	0.00486	CcSEcCtD
Cefuroxime—Mouth ulceration—Doxorubicin—liver cancer	0.00471	0.00485	CcSEcCtD
Cefuroxime—Blood alkaline phosphatase increased—Epirubicin—liver cancer	0.00469	0.00484	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Sorafenib—liver cancer	0.00469	0.00483	CcSEcCtD
Cefuroxime—Hepatic function abnormal—Epirubicin—liver cancer	0.00467	0.00481	CcSEcCtD
Cefuroxime—Pain—Sorafenib—liver cancer	0.00464	0.00479	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Sorafenib—liver cancer	0.00444	0.00458	CcSEcCtD
Cefuroxime—Thrombophlebitis—Doxorubicin—liver cancer	0.00436	0.0045	CcSEcCtD
Cefuroxime—Blood alkaline phosphatase increased—Doxorubicin—liver cancer	0.00434	0.00448	CcSEcCtD
Cefuroxime—Hepatic function abnormal—Doxorubicin—liver cancer	0.00432	0.00445	CcSEcCtD
Cefuroxime—Urticaria—Sorafenib—liver cancer	0.00431	0.00445	CcSEcCtD
Cefuroxime—Abdominal pain—Sorafenib—liver cancer	0.00429	0.00442	CcSEcCtD
Cefuroxime—Body temperature increased—Sorafenib—liver cancer	0.00429	0.00442	CcSEcCtD
Cefuroxime—Renal impairment—Epirubicin—liver cancer	0.00429	0.00442	CcSEcCtD
Cefuroxime—Cefonicid—ALB—liver cancer	0.00411	0.138	CrCbGaD
Cefuroxime—Hypersensitivity—Sorafenib—liver cancer	0.004	0.00412	CcSEcCtD
Cefuroxime—Renal impairment—Doxorubicin—liver cancer	0.00397	0.00409	CcSEcCtD
Cefuroxime—Pruritus—Sorafenib—liver cancer	0.00384	0.00396	CcSEcCtD
Cefuroxime—Blood creatinine increased—Epirubicin—liver cancer	0.00382	0.00394	CcSEcCtD
Cefuroxime—Diarrhoea—Sorafenib—liver cancer	0.00372	0.00383	CcSEcCtD
Cefuroxime—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.00368	0.00379	CcSEcCtD
Cefuroxime—Dizziness—Sorafenib—liver cancer	0.00359	0.0037	CcSEcCtD
Cefuroxime—Blood creatinine increased—Doxorubicin—liver cancer	0.00354	0.00365	CcSEcCtD
Cefuroxime—Eosinophilia—Epirubicin—liver cancer	0.00349	0.0036	CcSEcCtD
Cefuroxime—Vomiting—Sorafenib—liver cancer	0.00345	0.00356	CcSEcCtD
Cefuroxime—Rash—Sorafenib—liver cancer	0.00342	0.00353	CcSEcCtD
Cefuroxime—Dermatitis—Sorafenib—liver cancer	0.00342	0.00353	CcSEcCtD
Cefuroxime—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.0034	0.00351	CcSEcCtD
Cefuroxime—Headache—Sorafenib—liver cancer	0.0034	0.00351	CcSEcCtD
Cefuroxime—Bronchitis—Epirubicin—liver cancer	0.00339	0.0035	CcSEcCtD
Cefuroxime—Pancytopenia—Epirubicin—liver cancer	0.00335	0.00345	CcSEcCtD
Cefuroxime—Dysuria—Epirubicin—liver cancer	0.0033	0.0034	CcSEcCtD
Cefuroxime—Neutropenia—Epirubicin—liver cancer	0.0033	0.0034	CcSEcCtD
Cefuroxime—Upper respiratory tract infection—Epirubicin—liver cancer	0.00328	0.00338	CcSEcCtD
Cefuroxime—Eosinophilia—Doxorubicin—liver cancer	0.00323	0.00333	CcSEcCtD
Cefuroxime—Nausea—Sorafenib—liver cancer	0.00323	0.00332	CcSEcCtD
Cefuroxime—Infestation NOS—Epirubicin—liver cancer	0.00315	0.00324	CcSEcCtD
Cefuroxime—Infestation—Epirubicin—liver cancer	0.00315	0.00324	CcSEcCtD
Cefuroxime—Drowsiness—Epirubicin—liver cancer	0.00315	0.00324	CcSEcCtD
Cefuroxime—Bronchitis—Doxorubicin—liver cancer	0.00314	0.00324	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00312	0.00321	CcSEcCtD
Cefuroxime—Pancytopenia—Doxorubicin—liver cancer	0.0031	0.0032	CcSEcCtD
Cefuroxime—Renal failure—Epirubicin—liver cancer	0.00309	0.00319	CcSEcCtD
Cefuroxime—Jaundice—Epirubicin—liver cancer	0.00307	0.00316	CcSEcCtD
Cefuroxime—Stomatitis—Epirubicin—liver cancer	0.00307	0.00316	CcSEcCtD
Cefuroxime—Urinary tract infection—Epirubicin—liver cancer	0.00306	0.00315	CcSEcCtD
Cefuroxime—Neutropenia—Doxorubicin—liver cancer	0.00305	0.00315	CcSEcCtD
Cefuroxime—Dysuria—Doxorubicin—liver cancer	0.00305	0.00315	CcSEcCtD
Cefuroxime—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00303	0.00313	CcSEcCtD
Cefuroxime—Sweating—Epirubicin—liver cancer	0.00302	0.00311	CcSEcCtD
Cefuroxime—Hepatobiliary disease—Epirubicin—liver cancer	0.00298	0.00307	CcSEcCtD
Cefuroxime—Sinusitis—Epirubicin—liver cancer	0.00295	0.00304	CcSEcCtD
Cefuroxime—Agranulocytosis—Epirubicin—liver cancer	0.00294	0.00303	CcSEcCtD
Cefuroxime—Infestation NOS—Doxorubicin—liver cancer	0.00291	0.003	CcSEcCtD
Cefuroxime—Drowsiness—Doxorubicin—liver cancer	0.00291	0.003	CcSEcCtD
Cefuroxime—Infestation—Doxorubicin—liver cancer	0.00291	0.003	CcSEcCtD
Cefuroxime—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.00289	0.00297	CcSEcCtD
Cefuroxime—Renal failure—Doxorubicin—liver cancer	0.00286	0.00295	CcSEcCtD
Cefuroxime—Haemoglobin—Epirubicin—liver cancer	0.00284	0.00293	CcSEcCtD
Cefuroxime—Stomatitis—Doxorubicin—liver cancer	0.00284	0.00292	CcSEcCtD
Cefuroxime—Jaundice—Doxorubicin—liver cancer	0.00284	0.00292	CcSEcCtD
Cefuroxime—Urinary tract infection—Doxorubicin—liver cancer	0.00283	0.00292	CcSEcCtD
Cefuroxime—Hepatitis—Epirubicin—liver cancer	0.00282	0.00291	CcSEcCtD
Cefuroxime—Haemorrhage—Epirubicin—liver cancer	0.00282	0.00291	CcSEcCtD
Cefuroxime—Sweating—Doxorubicin—liver cancer	0.00279	0.00288	CcSEcCtD
Cefuroxime—Urinary tract disorder—Epirubicin—liver cancer	0.00279	0.00287	CcSEcCtD
Cefuroxime—Urethral disorder—Epirubicin—liver cancer	0.00277	0.00285	CcSEcCtD
Cefuroxime—Hepatobiliary disease—Doxorubicin—liver cancer	0.00275	0.00284	CcSEcCtD
Cefuroxime—Sinusitis—Doxorubicin—liver cancer	0.00273	0.00281	CcSEcCtD
Cefuroxime—Agranulocytosis—Doxorubicin—liver cancer	0.00272	0.0028	CcSEcCtD
Cefuroxime—Erythema multiforme—Epirubicin—liver cancer	0.00267	0.00275	CcSEcCtD
Cefuroxime—Haemoglobin—Doxorubicin—liver cancer	0.00263	0.00271	CcSEcCtD
Cefuroxime—Haemorrhage—Doxorubicin—liver cancer	0.00261	0.00269	CcSEcCtD
Cefuroxime—Hepatitis—Doxorubicin—liver cancer	0.00261	0.00269	CcSEcCtD
Cefuroxime—Urinary tract disorder—Doxorubicin—liver cancer	0.00258	0.00266	CcSEcCtD
Cefuroxime—Angiopathy—Epirubicin—liver cancer	0.00256	0.00264	CcSEcCtD
Cefuroxime—Urethral disorder—Doxorubicin—liver cancer	0.00256	0.00264	CcSEcCtD
Cefuroxime—Immune system disorder—Epirubicin—liver cancer	0.00255	0.00263	CcSEcCtD
Cefuroxime—Chills—Epirubicin—liver cancer	0.00253	0.00261	CcSEcCtD
Cefuroxime—Erythema multiforme—Doxorubicin—liver cancer	0.00247	0.00255	CcSEcCtD
Cefuroxime—Erythema—Epirubicin—liver cancer	0.00246	0.00253	CcSEcCtD
Cefuroxime—Flatulence—Epirubicin—liver cancer	0.00242	0.0025	CcSEcCtD
Cefuroxime—Angiopathy—Doxorubicin—liver cancer	0.00237	0.00244	CcSEcCtD
Cefuroxime—Muscle spasms—Epirubicin—liver cancer	0.00236	0.00244	CcSEcCtD
Cefuroxime—Immune system disorder—Doxorubicin—liver cancer	0.00236	0.00243	CcSEcCtD
Cefuroxime—Chills—Doxorubicin—liver cancer	0.00234	0.00242	CcSEcCtD
Cefuroxime—Erythema—Doxorubicin—liver cancer	0.00228	0.00234	CcSEcCtD
Cefuroxime—Agitation—Epirubicin—liver cancer	0.00226	0.00233	CcSEcCtD
Cefuroxime—Flatulence—Doxorubicin—liver cancer	0.00224	0.00231	CcSEcCtD
Cefuroxime—Leukopenia—Epirubicin—liver cancer	0.0022	0.00227	CcSEcCtD
Cefuroxime—Muscle spasms—Doxorubicin—liver cancer	0.00219	0.00225	CcSEcCtD
Cefuroxime—Palpitations—Epirubicin—liver cancer	0.00217	0.00224	CcSEcCtD
Cefuroxime—Cough—Epirubicin—liver cancer	0.00215	0.00221	CcSEcCtD
Cefuroxime—Convulsion—Epirubicin—liver cancer	0.00213	0.0022	CcSEcCtD
Cefuroxime—Chest pain—Epirubicin—liver cancer	0.00209	0.00216	CcSEcCtD
Cefuroxime—Arthralgia—Epirubicin—liver cancer	0.00209	0.00216	CcSEcCtD
Cefuroxime—Agitation—Doxorubicin—liver cancer	0.00209	0.00215	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00208	0.00214	CcSEcCtD
Cefuroxime—Leukopenia—Doxorubicin—liver cancer	0.00204	0.0021	CcSEcCtD
Cefuroxime—Palpitations—Doxorubicin—liver cancer	0.00201	0.00207	CcSEcCtD
Cefuroxime—Anaphylactic shock—Epirubicin—liver cancer	0.00201	0.00207	CcSEcCtD
Cefuroxime—Cefazolin—ALB—liver cancer	0.00199	0.0671	CrCbGaD
Cefuroxime—Cough—Doxorubicin—liver cancer	0.00199	0.00205	CcSEcCtD
Cefuroxime—Convulsion—Doxorubicin—liver cancer	0.00197	0.00203	CcSEcCtD
Cefuroxime—Thrombocytopenia—Epirubicin—liver cancer	0.00196	0.00202	CcSEcCtD
Cefuroxime—Tachycardia—Epirubicin—liver cancer	0.00196	0.00202	CcSEcCtD
Cefuroxime—Skin disorder—Epirubicin—liver cancer	0.00195	0.00201	CcSEcCtD
Cefuroxime—Hyperhidrosis—Epirubicin—liver cancer	0.00194	0.002	CcSEcCtD
Cefuroxime—Chest pain—Doxorubicin—liver cancer	0.00194	0.002	CcSEcCtD
Cefuroxime—Arthralgia—Doxorubicin—liver cancer	0.00194	0.002	CcSEcCtD
Cefuroxime—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00192	0.00198	CcSEcCtD
Cefuroxime—Anorexia—Epirubicin—liver cancer	0.00191	0.00197	CcSEcCtD
Cefuroxime—Ceftriaxone—ALB—liver cancer	0.00189	0.0636	CrCbGaD
Cefuroxime—Anaphylactic shock—Doxorubicin—liver cancer	0.00186	0.00191	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00183	0.00188	CcSEcCtD
Cefuroxime—Thrombocytopenia—Doxorubicin—liver cancer	0.00182	0.00187	CcSEcCtD
Cefuroxime—Tachycardia—Doxorubicin—liver cancer	0.00181	0.00187	CcSEcCtD
Cefuroxime—Skin disorder—Doxorubicin—liver cancer	0.0018	0.00186	CcSEcCtD
Cefuroxime—Hyperhidrosis—Doxorubicin—liver cancer	0.00179	0.00185	CcSEcCtD
Cefuroxime—Dyspnoea—Epirubicin—liver cancer	0.00179	0.00184	CcSEcCtD
Cefuroxime—Somnolence—Epirubicin—liver cancer	0.00178	0.00184	CcSEcCtD
Cefuroxime—Anorexia—Doxorubicin—liver cancer	0.00177	0.00182	CcSEcCtD
Cefuroxime—Dyspepsia—Epirubicin—liver cancer	0.00177	0.00182	CcSEcCtD
Cefuroxime—Decreased appetite—Epirubicin—liver cancer	0.00174	0.0018	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Epirubicin—liver cancer	0.00173	0.00179	CcSEcCtD
Cefuroxime—Pain—Epirubicin—liver cancer	0.00172	0.00177	CcSEcCtD
Cefuroxime—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00169	0.00174	CcSEcCtD
Cefuroxime—Dyspnoea—Doxorubicin—liver cancer	0.00166	0.00171	CcSEcCtD
Cefuroxime—Cefalotin—ALB—liver cancer	0.00165	0.0557	CrCbGaD
Cefuroxime—Somnolence—Doxorubicin—liver cancer	0.00165	0.0017	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Epirubicin—liver cancer	0.00164	0.00169	CcSEcCtD
Cefuroxime—Dyspepsia—Doxorubicin—liver cancer	0.00163	0.00168	CcSEcCtD
Cefuroxime—Decreased appetite—Doxorubicin—liver cancer	0.00161	0.00166	CcSEcCtD
Cefuroxime—Gastrointestinal disorder—Doxorubicin—liver cancer	0.0016	0.00165	CcSEcCtD
Cefuroxime—Urticaria—Epirubicin—liver cancer	0.00159	0.00164	CcSEcCtD
Cefuroxime—Pain—Doxorubicin—liver cancer	0.00159	0.00164	CcSEcCtD
Cefuroxime—Abdominal pain—Epirubicin—liver cancer	0.00159	0.00163	CcSEcCtD
Cefuroxime—Body temperature increased—Epirubicin—liver cancer	0.00159	0.00163	CcSEcCtD
Cefuroxime—Gastrointestinal pain—Doxorubicin—liver cancer	0.00152	0.00156	CcSEcCtD
Cefuroxime—Cephalexin—ALB—liver cancer	0.0015	0.0506	CrCbGaD
Cefuroxime—Hypersensitivity—Epirubicin—liver cancer	0.00148	0.00152	CcSEcCtD
Cefuroxime—Urticaria—Doxorubicin—liver cancer	0.00148	0.00152	CcSEcCtD
Cefuroxime—Body temperature increased—Doxorubicin—liver cancer	0.00147	0.00151	CcSEcCtD
Cefuroxime—Abdominal pain—Doxorubicin—liver cancer	0.00147	0.00151	CcSEcCtD
Cefuroxime—Pruritus—Epirubicin—liver cancer	0.00142	0.00146	CcSEcCtD
Cefuroxime—Diarrhoea—Epirubicin—liver cancer	0.00137	0.00142	CcSEcCtD
Cefuroxime—Hypersensitivity—Doxorubicin—liver cancer	0.00137	0.00141	CcSEcCtD
Cefuroxime—Dizziness—Epirubicin—liver cancer	0.00133	0.00137	CcSEcCtD
Cefuroxime—Pruritus—Doxorubicin—liver cancer	0.00131	0.00135	CcSEcCtD
Cefuroxime—Vomiting—Epirubicin—liver cancer	0.00128	0.00131	CcSEcCtD
Cefuroxime—Diarrhoea—Doxorubicin—liver cancer	0.00127	0.00131	CcSEcCtD
Cefuroxime—Rash—Epirubicin—liver cancer	0.00127	0.0013	CcSEcCtD
Cefuroxime—Dermatitis—Epirubicin—liver cancer	0.00126	0.0013	CcSEcCtD
Cefuroxime—Headache—Epirubicin—liver cancer	0.00126	0.0013	CcSEcCtD
Cefuroxime—Dizziness—Doxorubicin—liver cancer	0.00123	0.00127	CcSEcCtD
Cefuroxime—Nausea—Epirubicin—liver cancer	0.00119	0.00123	CcSEcCtD
Cefuroxime—Vomiting—Doxorubicin—liver cancer	0.00118	0.00122	CcSEcCtD
Cefuroxime—Rash—Doxorubicin—liver cancer	0.00117	0.00121	CcSEcCtD
Cefuroxime—Dermatitis—Doxorubicin—liver cancer	0.00117	0.00121	CcSEcCtD
Cefuroxime—Headache—Doxorubicin—liver cancer	0.00116	0.0012	CcSEcCtD
Cefuroxime—Nausea—Doxorubicin—liver cancer	0.0011	0.00114	CcSEcCtD
